Pipeline Injection Study Sample Clauses

Pipeline Injection Study. A total of five irrigation pipelines within three irrigation districts were used to test the injection of soluble KCl into pipelines to achieve a target concentration of 100 mg L-1 K+. Three pipelines (Pipelines A, B, C) in the EID, one pipeline (Pipeline D) in the Taber Irrigation District (TID), and one pipeline (Pipeline E) in the St. Xxxx River Irrigation District (SMRID) were used in the study (Table 1; Figure 1).
AutoNDA by SimpleDocs
Pipeline Injection Study. Potassium Chloride Injection and Purging. The injection of the KCl stock solution was carried out successfully at all five pipeline trials. The efforts required for pipeline treatment were much greater for the larger pipelines with multiple irrigation systems in terms of coordination of irrigators and the irrigation districts. For the four pipeline trials carried out in 2017, not all of the irrigation systems were used in the trials. About half the systems serviced by Pipelines B, C, and D were used, and nearly all of the systems serviced by Pipeline E were used (Table 1). There were a number of reasons why irrigators did not participate either in whole or in part. These reasons included not being interested in the project, concerns about possible effects on their crop, interference with crop management practices (e.g., pollination by bees), and unexpected last-minute changes that prevented an irrigator from operating their pivot system(s). Other factors such as limited window-of-opportunities relative to main agronomic activities, including seeding, pesticide application, and harvesting, had to be considered. The time required to inject the KCl stock solution into the pipelines varied from 1.1 to 6.1 h (Table 2). The length of time was a function of the total pipeline volume (Table 1) and the number of irrigation systems in operation at a given time. Even though Pipeline E was larger than Pipelines B and C, the time required to treat the former pipeline was about 30 to 40% less time. This was because only two to three pivot systems were operated during the Pipeline B and C trials; whereas, up to five pivots were operated at the same time during the Pipeline E trial. As a result, the flow was higher through Pipeline E. The injection of Pipeline D took about 2.3 to 3.8 times longer to inject with KCl solution than the other four pipelines (Table 2). This is mainly because Pipeline D was three to four times larger than the other three pipelines. Even though Pipeline D had a larger number of irrigation systems used in the trial, not all of the irrigation systems were operated at the same time.

Related to Pipeline Injection Study

  • Feasibility Study Buyer will, at Buyer's expense and within ____ days from Effective Date ("Feasibility Study Period"), determine whether the Property is suitable, in Buyer's sole and absolute discretion, for ___________________ use. During the Feasibility Study Period, Buyer may conduct a Phase I environmental assessment and any other tests, analyses, surveys and investigations ("Inspections") that Buyer deems necessary to determine to Buyer's satisfaction the Property's engineering, architectural and environmental properties; zoning and zoning restrictions; subdivision statutes; soil and grade; availability of access public roads, water, and other utilities; consistency with local, state and regional growth management plans, availability of permits, government approvals, and licenses; and other inspections that Buyer deems appropriate to determine the Property's suitability for the Buyer's intended use. If the Property must be rezoned, Buyer will obtain the rezoning from the appropriatx xxxernment agencies. Seller will sign all documents Buyer is required to file in connection with development or rezoning approvals. Seller gives Buyer, its agents, contractors and assigns, the right to enter the Property at any time during the Feasibility Study Period for the purpose of conducting inspections; provided, however, that Buyer, its agents, contractors and assigns enter the Property and conduct inspections at their own risk. Buyer will indemnify and hold Seller harmless from xxxxes, damages, costs, claims and expenses of any nature, including attorney's fees, expenses and liability incurred in application for rezoning or related proceedings, and from liability to any person, arising from the conduct of any and all inspections of any work authorized by Buyer. Buyer will not engage in any activity that xxxxx result in a construction lien being filed against the Property without Seller's prior written consent. If this transaction does not close, Buyer will, at Buyer's expense, (1) repair all damages to the Property resulting from the Inspections and return the Property to the condition it was in prior to conduct of the Inspections, and (2) release to Seller all reports and other work generated as a result of the Inspections. Buyer will deliver written notice to Seller prior to the expiration of the Feasibility Study Period of Buyer's determination of whether or not the Properxx xx acceptable. Buyer's failure to comply with this notice requirement will constitute acceptance of the Property as suitable for Buyer's intended use in its "as is" condition. If the Property is unacceptable to Buyer and written notice of this fact is timely delivered to Seller, this Contract will be deemed terminated as of the day after the Feasibility Study period ends and Buyer's deposit(s) will be returned after Escrow Axxxx receives proper authorization form all interested parties.

  • Transporting Students Teachers shall not be required to transport a student in a private vehicle on behalf of the school.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

  • System Impact Study An assessment by the Transmission Provider of (i) the adequacy of the Transmission System to accommodate a Completed Application, an Interconnection Request or an Upgrade Request, (ii) whether any additional costs may be incurred in order to provide such transmission service or to accommodate an Interconnection Request, and (iii) with respect to an Interconnection Request, an estimated date that an Interconnection Customer’s Customer Facility can be interconnected with the Transmission System and an estimate of the Interconnection Customer’s cost responsibility for the interconnection; and (iv) with respect to an Upgrade Request, the estimated cost of the requested system upgrades or expansion, or of the cost of the system upgrades or expansion, necessary to provide the requested incremental rights.

  • Interconnection Product Options Interconnection Customer has selected the following (checked) type of Interconnection Service:

  • Trials The Ship shall run the following test and trials:

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

Time is Money Join Law Insider Premium to draft better contracts faster.